Royalty Pharma (RPRX) Stock Forecast & Price Target

$58.60 +0.04 (+0.07%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$58.59 -0.01 (-0.02%)

As of 08/14/2026 07:55 PM Eastern

Compare

Royalty Pharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
0

Buy
8

Based on 8 Wall Street analysts who have issued ratings for Royalty Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for RPRX.

Consensus Price Target

$60.86
3.85% Upside

According to the 8 analysts' twelve-month price targets for Royalty Pharma, the average price target is $60.86. The highest price target for RPRX is $66.00, while the lowest price target for RPRX is $45.00. The average price target represents a forecasted upside of 3.85% from the current price of $58.60.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RPRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Royalty Pharma and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RPRX Analyst Ratings Over Time

Type	Current Forecast 8/15/25 to 8/15/26	1 Month Ago 7/16/25 to 7/16/26	3 Months Ago 5/17/25 to 5/17/26	1 Year Ago 8/15/24 to 8/15/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$60.86	$56.57	$53.71	$48.00
Forecasted Upside	3.85% Upside	-3.35% Downside	1.64% Upside	32.05% Upside
Consensus Rating	Buy	Buy	Buy	Buy

RPRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RPRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Royalty Pharma Stock vs. The Competition

Type	Royalty Pharma	Healthcare Companies	Broader Market
Consensus Rating Score	3.00	2.30	2.53
Consensus Rating	Buy	Hold	Moderate Buy
Predicted Upside	3.85% Upside	785.25% Upside	11.05% Upside
News Sentiment Rating	Positive News See Recent RPRX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/12/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Buy (B-)
8/7/2026	JPMorgan Chase & Co. 3 of 5 stars	Chris Schott 4 of 5 stars	Boost Target	Overweight	$58.00 ➝ $62.00	+8.58%
8/6/2026	The Goldman Sachs Group 3 of 5 stars		Reiterated Rating	Buy	$66.00	+15.37%
8/6/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$65.00	+12.55%
8/5/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
7/13/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Scala Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$50.00 ➝ $65.00	+15.95%
5/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$50.00 ➝ $66.00	+31.47%
4/21/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashwani Verma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$51.00 ➝ $57.00	+15.62%
12/11/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$45.00	+17.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:47 PM ET.

Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 11, 2026. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com.

Royalty Pharma
Bull Case

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

The company has a diversified portfolio consisting of royalties on approximately 35 commercial products and 14 development-stage product candidates, which can provide stability and growth potential.
Royalty Pharma plc operates in various therapeutic areas, including rare diseases and cancer, which are high-demand sectors in the biopharmaceutical industry.
The current stock price is around $45, reflecting a strong market position and investor interest in the company's unique business model.
With a dividend payout ratio of approximately 63.95%, Royalty Pharma plc offers attractive returns to shareholders, making it appealing for income-focused investors.
The company engages in non-dilutive financing, allowing it to support drug developers without affecting their equity, which can lead to more sustainable growth.

Royalty Pharma
Bear Case

Investors should be bearish about investing in Royalty Pharma plc for these reasons:

The biopharmaceutical industry is highly competitive, and the success of Royalty Pharma plc depends on the performance of the products it has royalties on, which can be unpredictable.
As a specialty finance company, Royalty Pharma plc's revenue is tied to the commercial success of its partners, which may expose it to risks if those products underperform.
Market volatility can impact the stock price significantly, and recent fluctuations may deter risk-averse investors.
Investors may face challenges in assessing the long-term viability of the development-stage product candidates in the portfolio, as many are still in the early phases of clinical trials.
Changes in regulatory environments can affect the biopharmaceutical sector, potentially impacting the revenue streams that Royalty Pharma plc relies on.

RPRX Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Royalty Pharma is $60.86, with a high forecast of $66.00 and a low forecast of $45.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPRX shares.

According to analysts, Royalty Pharma's stock has a predicted upside of 3.85% based on their 12-month stock forecasts.

Royalty Pharma has been rated by research analysts at Bank of America, JPMorgan Chase & Co., Morgan Stanley, TD Cowen, The Goldman Sachs Group, and Weiss Ratings in the past 90 days.

Analysts like Royalty Pharma more than other "healthcare" companies. The consensus rating for Royalty Pharma is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how RPRX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Royalty Pharma Recommendations

This page (NASDAQ:RPRX) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Stock Forecast & Price Target

Royalty Pharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

RPRX Analyst Ratings Over Time

RPRX Analyst Recommendations By Month

RPRX Price Targets by Month

Royalty Pharma Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

Royalty Pharma
Bull Case

Royalty Pharma
Bear Case

RPRX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Royalty Pharma Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Stock Forecast & Price Target

Royalty Pharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

RPRX Analyst Ratings Over Time

RPRX Analyst Recommendations By Month

RPRX Price Targets by Month

Royalty Pharma Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

Royalty Pharma Bull Case

Royalty Pharma Bear Case

RPRX Forecast - Frequently Asked Questions

What is Royalty Pharma's forecast for 2026?

Should I buy or sell Royalty Pharma stock right now?

Does Royalty Pharma's stock price have much upside?

What analysts cover Royalty Pharma?

Do Wall Street analysts like Royalty Pharma more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Royalty Pharma Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Royalty Pharma
Bull Case

Royalty Pharma
Bear Case